Global medication shortages between 2021 and 2024 have intensified, affecting both developed and developing countries and impacting hospitals, pharmacies, and patient care .

In France, reported drug shortages rose from 2,160 in 2021 to 4,925 in 2023, with 44% of people experiencing a shortage in 2023 .

The United States faced critical shortages of chemotherapy drugs—72% of cancer centers reported carboplatin shortages and 59% reported cisplatin shortages, leading to treatment delays and rationing .

Penicillin G benzathine, essential for syphilis treatment, was also in short supply, prompting rationing and consideration of a public health emergency .

Ireland experienced shortages of paracetamol during the 2022–2023 flu season, while Nigeria faced imminent scarcity of essential medications due to economic downturns and supply chain disruptions .

The causes of these shortages are multifactorial.

Supply chain disruptions, manufacturing difficulties, and shortages of raw materials have been exacerbated by the COVID-19 pandemic, which disrupted global manufacturing and distribution .

Increased demand for medications, driven by rising rates of chronic and infectious diseases, further strained supplies .

Regulatory and procurement challenges, such as delayed tenders and payment issues, contributed to shortages in regions like Karnataka, India .

Industry consolidations and prioritization of newer, more profitable drugs over older generics also played a role, particularly in chemotherapy drug shortages .

Healthcare systems have responded with a range of coping strategies.

Providers have prioritized and rationed scarce drugs, switched patients to alternative medications within the same class, and adjusted treatment regimens to ensure continuity of care .

The FDA allowed importation of chemotherapy drugs from overseas, and the European Commission proposed a "voluntary solidarity mechanism" for EU countries to share medicines and establish early warning

Global medication shortages between 2021 and 2024 have intensified, affecting both developed and developing countries and impacting hospitals, pharmacies, and patient care .

Title:

Content: Advertisement

U.S. cancer centers report ongoing shortage of chemotherapy drugs

By Cara Murez, HealthDay News
In all, 72% of cancer centers surveyed reported a continued shortage of carboplatin. And 59% were still seeing a shortage of cisplatin. Photo by klbz/Pixabay

U.S. cancer centers continue to have shortages of commonly used chemotherapy drugs, a new survey shows, though the medications are not as scarce as they were last June.

The National Comprehensive Cancer Network (NCCN), a nonprofit alliance of leading cancer centers, surveyed its network in September.

In all, 72% of cancer centers surveyed reported a continued shortage of carboplatin. And 59% were still seeing a shortage of cisplatin.

Advertisement

These two platinum-based generic chemotherapy medications are recommended for treating many different cancers. Overall, 86% of centers surveyed said they were short on at least one type of anti-cancer drug. A survey in June showed that 93% of cancer centers had a shortage of carboplatin, and 70% of cisplatin.

"Everyone with cancer should have access to the best possible treatment according to the latest evidence and expert consensus guidelines," said Dr. Robert Carlson, chief executive officer for NCCN.

Advertisement

"Drug shortages aren't new, but the widespread impact makes this one particularly alarming. It is extremely concerning that this situation continues despite significant attention and effort over the past few months. We need enduring solutions in order to safeguard people with cancer and address any disparities in care," Carlson said in a NCCN news release. Twenty-nine of the NCCN's member institutions responded to the September survey. They include leading academic centers across the United States. The findings may not reflect additional challenges that smaller community practices serving rural and marginalized patients are experiencing. The centers surveyed were using strict waste management strategies, so nearly all were still able to provide the medications to all patients who needed them. Other medications in short supply included methotrexate, with 66% of centers reporting a shortage; 5-fluorouracil, with 55% falling short; fludarabine at 45%; and hydrocortisone at 41%.

"These drug shortages are the result of decades of systemic challenges," said Alyssa Schatz, NCCN's senior director of policy and advocacy. "We recognize that comprehensive solutions take time."

Schatz said the network appreciates those who have put forth proposals to improve investment in generics.

"At the same time, we have to acknowledge that the cancer drug shortage has been ongoing for months, which is unacceptable for anyone impacted by cancer today," Schatz said. "These new survey results remind us that we are still in an ongoing crisis and must respond with appropriate urgency."

Advertisement

The organization is continuing to advocate for more supplies.

CNN recently reported that two other drugs used for cancer, vinblastine and dacarbazine, went into shortage in September.

"These drugs are particularly used to treat patients with Hodgkin's lymphoma. Hodgkin's lymphoma is probably one of the most curable types of cancers out there," Dr. Doug Hawkins of the Children's Oncology Group, a research organization, told CNN.

"The problem is never-ending. It is horrible," he added. "I mean, to say to a patient, 'we know how to treat your child, but we can't get the drugs,' and this is America, and it's 2023 -- it's crazy."

More information

The White House has more on strengthening the supply chain for cancer drugs.

Copyright © 2023 HealthDay. All rights reserved.

Latest Headlines

Title:

Content: 2 major drugs are in short supply, FDA says. Both are widely prescribed to children.

NEW!

Drug shortages continue in the U.S., even as the COVID-19 pandemic nears the end of its third year.

Two drugs commonly prescribed to children — Adderall and liquid amoxicillin — recently joined the list, the Food and Drug Administration says.

The FDA announced last month that it was talking to manufacturers about a shortage of Adderall, the combination drug of amphetamine mixed salts used to treat attention deficit hyperactivity disorder.

Parents are also discovering liquid amoxicillin — an important antibiotic used to treat bacterial infections — is in short supply, according to the FDA. It added the oral solution of the antibiotic to its list of drug shortages on Oct. 28.

Both drugs are widely used by children as well as adults. The amoxicillin shortage comes at a vulnerable time, as we enter cold and flu season and U.S. hospitals continue to fill with respiratory infections. Amoxicillin is often used to treat ear infections and bronchitis.

The reason for the shortages? The FDA didn’t immediately respond to a request for comment Thursday. However, the agency cited a few factors on its website, including quality and manufacturing issues.

“There have been other reasons such as production delays at the manufacturer and delays companies have experienced receiving raw materials and components from suppliers,” the agency says. “Discontinuations are another factor contributing to shortages.

“FDA can’t require a firm to keep making a drug it wants to discontinue. Sometimes these older drugs are discontinued by companies in favor of newer, more profitable drugs.”

For a list of all drugs currently in short supply, visit FDA.gov.

Our journalism needs your support. Please subscribe today to NJ.com.

Spencer Kent may be reached at skent@njadvancemedia.com.

If you purchase a product or register for an account through one of the links on our site, we may receive compensation.

Title:

Content: Last Updated:

Karnataka Government Faces Heat Over Shortage Of Medicines In Govt Hospitals

Pharma companies blame state medical supplies corp for not clearing dues, say won’t participate in tender until payments are cleared.

General News

| Written By
Prajwal Prasad

Karnataka health minister Dinesh Gundu Rao blamed KSMSCL for delay in floating tenders. (Image: PTI/File photo)

Even after three months of the formation of the new government in Karnataka, the state still seems to be grappling with a shortage of medicines in government medical facilities. The Congress-led government has also admitted that there’s a scarcity of life-saving drugs in the state.

A total of 733 medicines worth Rs 600 crore was needed for the current year in the state. However, due to the alleged negligence of the officials of the Karnataka State Medical Supplies Corporation (KSMSCL) under the health department, there is a shortage of medicines to treat serious ailments in government hospitals. As a result, patients are reportedly struggling to get life-saving medicines.

Delay in clearing dues discourage pharma companies from participating in tenders

In addition, pharma companies have reportedly been reluctant to participate in tenders due to delays in disposal of pending bills, with the number of companies participating in the tender coming down this year as compared to last year. A representative from a pharma company, speaking to Republic on the condition of anonymity, said, "Many of our bills are pending despite giving the requisite documents and stocks allotted details to the officials. This will result in huge losses for the firm and this is not the first time such a thing is happening. We will participate in the tender only when the bills are cleared."

KSMSCL procures various medicines, including bandage cloth, cotton, surgical gloves, antibiotic tablets and medical equipment, and supplies them to government hospitals. However, the corporation was supposed to complete the tender process by May this year and procure and stock all kinds of medicines and medical equipment, whereas the corporation is running late by three months.

Will float tender once in two years to tackle medicine shortage: State health minister

Karnataka Health Minister Dinesh Gundu Rao, speaking to the media, said, "It is true that there is a shortage of medicines in the state. Due to the negligence of some officials of KSMSCL, the tender could not be completed within the stipulated time and the medicines could not be stocked. In the coming days, tenders will be called once in two years instead of annual tenders to prevent shortage of medicines."

Pending bills for pharma companies yet to be cleared

As the corporation is dragging its feet on the process of clearing bills, pharma companies that have supplied 100 per cent of the medicines to KSMSCL are allegedly not being paid on time. Security deposits and EMDs are also pending. Though there is a rule that those supplying medicines have to be paid within 30 days, it is reportedly not being followed. An estimated Rs 30-40 crore was supplied to 'Namma clinics' under the National Health Mission (NHM) by the corporation. The medicine and medical equipment bills have not been paid yet. Also, no funds have been released to the corporation by the health department. Rs 90 crore for medicines and Rs 40 crore for medical equipment, which sums up to a total of Rs 130 crore, are pending and yet to be released by the health department.

Relatives of patients running from pillar to post for medicines

There is an apparent shortage of medicines for various ailments in government hospitals. Apart from tablets, there’s a paucity of injections, glucose, bandages and surgical equipment.

Attendants, caretakers and relatives of patients are complaining that they are struggling to find life-saving drugs and over-the-counter medicines. Beerappa, a caretaker, speaking to Republic, said, “We are being made to run around for some medicines as they are not available easily at hospitals. This causes a lot of problems for us, and when we question the pharmacist, they say there's no stock. We urge the government to take stock of the situation and not play with the lives of innocents."

First Published:

In France, reported drug shortages rose from 2,160 in 2021 to 4,925 in 2023, with 44% of people experiencing a shortage in 2023 .

The United States faced critical shortages of chemotherapy drugs—72% of cancer centers reported carboplatin shortages and 59% reported cisplatin shortages, leading to treatment delays and rationing .

Title:

Content: Prescription drug shortages lead to higher prices

Reporter: Andryanna Sheppard
Published: Updated:
Lea este artículo en Noticias WINK

Millions of people in the United States depend on prescription drugs to manage pain, treat medical conditions, and even to help them stay alive. However, the country’s drug shortage is making it hard for some people to get the medication they need or pay for the drugs that are available.

Federal Drug Administration data shows 90 percent of prescriptions in the US are for generic drugs. According to the National Institutes of Health, most prescription drugs involved in shortages are generic options.

There are currently more than 250 medications on the nation’s prescription drug shortage list, according to the American Society of Health-System Pharmacists. The organization says 2023 marked the worst year for shortages in about a decade.

Jessica Kahn’s two sons were diagnosed with ADD.

“I would say tricky, tricky to navigate,” Kahn described.

For the past year, Kahn said getting their medication has been frustrating.

“I have my list of all the pharmacies. I’ve even driven all the way up north to Walgreens or a CVS, some random place to go pick up a kids’ prescription,” Kahn added.

According to the FDA, prescription drug shortages are often linked to manufacturing and quality problems, delays, and discontinuations. Two drugs used in chemotherapy, Adderall, lidocaine, and amoxicillin are just a couple of the prescription medications on the shortage list.

When drug supplies are low, prices tend to increase. According to the US Department of Health and Human Services, there is a 16.6 percent increase in the price of drugs involved in a shortage. And in some cases, alternative drugs were priced at least three times higher.

“You got to be very conscientious that it might not be available and that it is not an option,” Kahn advised. “No matter how many places you call, it’s not there.”

Beating the prescription drug shortage

Health experts offer these tips:

  • Check the national drug shortage list for your medication and possible alternatives.
  • Don’t wait until your prescription is almost gone to refill it.
  • Check other pharmacies for availability and if you can’t find the generic version, look for coupons or programs that offer payment help. Some patients have reported that they receive additional help to reduce some prescription costs from $100 to $10, it’s not allowed if you are already on Medicare.
  • Websites and apps like GoodRX, RX Saver and WellRX can help you find the cheapest place that has your medication and coupons for it.

Contributors to this news report include: Lindsay Dailey, Producer; Bob Walko, Editor

Copyright ©2024 Fort Myers Broadcasting. All rights reserved.

This material may not be published, broadcast, rewritten, or redistributed without prior written consent.

Penicillin G benzathine, essential for syphilis treatment, was also in short supply, prompting rationing and consideration of a public health emergency .

Title:

Content: As drug shortage list grows, many hospitals face tough decisions on rationing care

More than half of hospital pharmacists are reporting a critical shortage of chemotherapy drugs and nearly all are reporting overall medicine supply gaps as prescription drug shortages near an all time high, according to a new survey.

Hospital pharmacists said drug shortages have forced 1 in 3 health systems to delay, cancel or ration care or switch to alternate drugs to continue to treat patients. And 99% are reporting some drug supply shortages, an American Society of Health-System Pharmacists survey of more than 1,000 pharmacists released Thursday found.

The organization reported shortages of 309 drugs, near the all-time high of 320 shortages in 2014. The scarcity of key drugs is prompting hospitals to find or substitute drugs and change treatment plans as needed.

“In some cases, there are no alternatives to the affected drugs, which puts patients at risk," ASHP Chief Executive Officer Paul W. Abramowitz said in a statement. "This issue requires quick action from Congress to address the underlying causes of shortages and ensure patients have the medications they need.”

Cancer drug shortages

In June, the Food and Drug Administration said it will temporarily allow overseas drug manufacturers to import some chemotherapy drugs.

The FDA allowed Qilu Pharmaceutical, a drug manufacturer in China, to import the injectable chemotherapy drug cisplatin in 50-milligram vials. Toronto pharmaceutical company Apotex Corp. will distribute the medication in the United States.

More than a dozen cancer drugs have been in shortage in recent months, including cisplatin and carboplatin, used to treat lung, breast, prostate and gynecologic cancers. The National Cancer Institute said cisplatin and similar drugs are prescribed for 10% to 20% of all cancer patients.

In June, the National Comprehensive Cancer Network released a survey of 27 academic cancer centers that found 93% reported shortages of carboplatin and 70% faced shortages of cisplatin.

When cancer hospitals face such shortages, they attempt to make sure there's enough medication for patients to finish the course of treatment, said Mike Ganio, ASHP's senior director of pharmacy practice and quality.

Cancer hospitals facing such shortages might change medications for new patients starting on chemotherapy, said Ganio, a former pharmacy manager at an academic cancer center.

"You try to keep that patient on the same regimen as much as you can, unless they're failing it for some reason, and then you would switch," Ganio said.

Steroids, hormonal drugs also in short supply

More than 1 in 5 hospital pharmacists also reported shortages for steroids, hormonal drugs and oral liquids such as lidocaine, ibuprofen and amoxicillin.

A smaller number of pharmacists said heart medications, emergency prefilled syringes and drugs used for intensive care unit patients were in short supply. Others reported shortages of attention deficit hyperactivity disorder medicines, antimicrobial drugs and injectable opioids.

In all, about two-thirds of pharmacists said the shortages were "moderately impactful," which means they are managing shortages but patients are affected.

Pharmacists are managing the shortages by offering therapeutic alternatives, buying different vial sizes or concentrations and rationing medicines.

This article originally appeared on USA TODAY: Survey: Drug shortages are widespread, hospitals ration care

Ireland experienced shortages of paracetamol during the 2022–2023 flu season, while Nigeria faced imminent scarcity of essential medications due to economic downturns and supply chain disruptions .

Title:

Content: Today's Paper News Sports Features Business Opinion LEARNS Guide Newsletters Obits Games Archive Notices Core Values
ADVERTISEMENT
ADVERTISEMENT

Rise in syphilis, lack of penicillin worry officials

by Mark Dooley | Today at 4:00 a.m.

A shortage of penicillin to treat a skyrocketing number of syphilis cases is so dire that U.S. health officials are debating the need to declare a public health emergency, according to people familiar with the matter.

Major U.S. medical centers are rationing the recommended treatment for the deadly sexually transmitted disease because of a supply crunch. From Michigan to Missouri to Texas, some health care providers are prioritizing giving a key treatment -- penicillin G benzathine -- to pregnant patients and babies, because the drug can pass through the placenta and also treat the fetus.

Syphilis has been sickening more people over the past few years, but the latest surge in cases has been especially worrying to the federal government. The Department of Health and Human Services is mobilizing a new federal task force to tackle the problem, and staff members are discussing the possibility of declaring a public health emergency, which could give officials access to more funding to address the crisis, according to people familiar with the matter.

"This is a remarkable shortage," said Joseph Cherabie, an assistant professor at Washington University in St. Louis' medical school, who treats syphilis patients. Because of the need to conserve the drug for pregnant patients, other people are getting less-than-ideal treatments for the infection.

The government's efforts are being led by Assistant Secretary for Health Adm. Rachel Levine, according to one of the people, who asked not to be identified discussing private information. Levine has spent months recruiting experts to tackle the syphilis crisis, including officials at HHS, the Centers for Disease Control and Prevention and the Food and Drug Administration, which has been brought in to address ongoing drug shortages.

Levine and U.S. health officials at the CDC are weighing the benefits of the public health emergency declaration, such as the additional flexibility and money it would give HHS, one of the people said. They're also considering the potential drawbacks. Some are wary that a pandemic-fatigued public may consider it an overreaction and ignore similar declarations in the future. Ultimately, HHS Secretary Xavier Becerra has the power to make a declaration.

"The department is closely monitoring the alarming rise in cases of syphilis and will continue working to address this public health threat," an HHS spokesperson said.

Drug shortages, though not uncommon, have hit nine-year highs in the U.S. Over the past year there have been shortages of antibiotics, chemotherapies and ADHD medicines, to name a few.

The situation is partly a result of under-investment in manufacturing after years of falling generic drug prices. Companies have also been caught off-guard by unexpected changes in demand, creating far-reaching consequences that imperil lives.

The penicillin shortage began in April. The FDA said it was caused by increases in cases of syphilis and strep throat. Because a common antibiotic used to treat strep was in short supply this winter, patients were prescribed penicillin as an alternative, driving up demand for the drug.

That created an acute problem at a time when syphilis cases were rising precipitously. Rates of syphilis in 2021 were the highest since 1990, according to the most updated government data. In 2021, at least 176,000 cases of syphilis were reported, 32% more than the year before. The infection disproportionately impacts gay and bisexual men.

Pfizer Inc. is the only company that makes penicillin G benzathine for the U.S., selling it under the brand name Bicillin L-A.

The company has told the FDA that supply disruptions for the two most common doses of penicillin G benzathine will likely continue into the second quarter of 2024. Pfizer has added night and weekend shifts to increase production. To free up manufacturing resources, it's also deprioritized production of a smaller dose of Bicillin L-A that's not widely used.

Syphilis is especially dangerous for pregnant people, who can pass it on to a fetus, which often results in pregnancy loss, death of a baby shortly after birth or severe disability in children. Cases of this type of syphilis, called congenital syphilis, are also at their highest rates since the 1990s. In 2021, there were 2,855 cases reported, up 32% from the year prior. The disease is completely preventable with penicillin G benzathine.

Penicillin G benzathine is also often the most recommended treatment for people who aren't pregnant. Yet with supplies running short, the CDC is advising that doctors turn to another antibiotic, doxycycline. That's less convenient for patients, because doxycycline is a pill given twice a day for at least two weeks, whereas penicillin G benzathine is an injection that can sometimes clear the disease completely with one dose.

That makes doctors worry that some patients might not complete their treatment with doxycycline. Syphilis particularly affects people suffering from substance abuse, housing instability or homelessness, which makes it more difficult to sustain long-term medical care.

There's also less evidence backing the drug than there is for penicillin, according to physicians.

"We're learning in real time how effective doxycycline can be," Cherabie said.

Some states or health systems are directing doctors to use doxycycline for syphilis. The Michigan Department of Health and Human Services has instructed state-funded clinics to use doxycycline for certain patients because of the shortage, spokesperson Chelsea Wuth said.

At Houston Methodist, a health system with seven hospitals in the Houston area, penicillin G benzathine is reserved for pregnant patients and babies with syphilis, spokesperson Gale Smith said.

Some clinics have been able to get sufficient amounts of the Pfizer drug, at least for the time being. State-operated health clinics in South Carolina have been able to purchase as much as they need, a spokesperson for the health and environment department said.

While rates of HIV have been declining, other sexually transmitted diseases have become more prevalent in recent years. Condom use has fallen as more effective medications for HIV have become available, leaving people vulnerable to illnesses like syphilis, chlamydia and gonorrhea.

There are also fewer resources to identify people who need treatment and get them help. STD prevention work happens largely at local and state public-health departments, which have been losing money and staff over the years. The covid-19 pandemic diverted already scarce public health resources away from STD work.

The rise in syphilis cases is also prompting concern at a state level. Last year, New Mexico renewed a statewide public health order mandating that health care providers screen pregnant women for syphilis multiple times to catch the disease. The state had only one case of congenital syphilis reported in 2017. It had 42 in 2020.

Print Headline: Rise in syphilis, lack of penicillin worry officials

ADVERTISEMENT

Sponsor Content

ADVERTISEMENT
ADVERTISEMENT

The causes of these shortages are multifactorial.

Supply chain disruptions, manufacturing difficulties, and shortages of raw materials have been exacerbated by the COVID-19 pandemic, which disrupted global manufacturing and distribution .

Title:

Content: ×

Most Widely Read Newspaper

Scarcity of essential drugs imminent, industrial pharmacists warn

The Association of Industrial Pharmacists of Nigeria has warned that there may be a scarcity of essential medications across the country due to the current economic downturn.

The National Chairman of NAIP, Kenneth Onuegbu said the pharmaceutical companies may not be able to provide crucial medications if the government does not address and find a solution to the high cost of diesel and forex scarcity.

The World Health Organsation described essential medicines as those that satisfy the priority healthcare needs of a population.

According to WHO, essential medicines can save lives and improve health and are selected with due regard to disease prevalence, public health relevance, evidence of efficacy and safety, and comparative cost-effectiveness.

Speaking at the 5th Annual International Conference of the Nigerian Association of Foreign Trained Pharmacists, held at Sheraton Hotel, Ikeja, Lagos State, the NAIP chairman lamented that the current economic situation of the country has affected production and importation of medications.

While listing poor infrastructure, forex scarcity, and regulations as key issues affecting the pharmaceutical sector, Onuegbu urged the federal government to intervene in providing an enabling environment for producers.

“Poor infrastructure is a major challenge. Buying diesel is a very big headache for pharmaceutical companies.

“We have insecurity issues, and how to get the medication from the point of production to the final consumer is another challenge that we have not been able to solve.

“To access forex is a big challenge. The process can take a year to get the CBN subsidised rate, hence, we resort to the black market. You can imagine that we buy drugs at the rate of N1,100, and automatically, it will affect production.

“If we don’t do something about it, there is going to be a scarcity of essential medicines. We must call for the domestication of medications to reduce the production cost.

“It is also important to note that our environment is over-regulated. Our regulation ought to have a Nigeria face; we cannot be promoting local production when you are making it difficult for them to start.

“Government needs to tackle insecurity, epileptic power supply, forex and host of others if they really want pharmaceutical companies to survive in this country.”

In his remarks, the President of NAFTraph, Dr. John Ejezie blamed the current high price of medicine on supply chain challenges and high inflation rates.

He lamented that the current depreciation of the Naira had reduced the purchasing power of the citizenry and affected the production of drugs.

While describing the challenges plaguing the pharmaceutical sector as a big obstacle for Nigerian pharmacists, Ejezie maintained that the association will continue to reshape the health indicators through community-based free wellness efforts.

“These socio-economic menaces are experienced across the globe, and developing economies are disproportionately impacted due to non-robust socio-economic structures that might absorb such societal and economic shocks.

“Despite all these societal menaces and socio-economic challenges, we can’t let those wonderful dreams and aspirations dissipate, or anyone or circumstances kill them,” he added.

  • UPDATE NEWS: Nigerians can now be paid monthly in foreign currency, Naira or Dollars, you decide. Step by step on how to start. Click here

    BREAKING NEWS: 🚨 Could today be the day you change your life forever? 🌠 Dive into the chance to win a whopping $1.2 Billion* in the US Powerball Jackpot! 🎉💰 Imagine the possibilities! 🌍✨ Don't miss out! Join the excitement at 24Lottos.com - TAP HERE! 🚀🎯

  • X

    Stay informed!

    Never miss what matters with our daily free newsletter delivered into your inbox either in the morning or evening.

Increased demand for medications, driven by rising rates of chronic and infectious diseases, further strained supplies .

Title:

Content: Begin typing your search above and press return to search.

India's pharma exports clock double-digit growth amid surging demand in US, UK

By IANS

New Delhi, June 18: India’s pharmaceutical exports continue to register double-digit growth, reflecting the strong demand for the country’s affordable generic medicines in global markets led by the USA and UK.

India’s pharma exports grew by 10.45 per cent in May this year to touch the $2.3 billion mark compared with the $2.08 billion in the same month of the previous financial year. “It is moving in a positive way and we are optimistic of sustaining growth of not less than 10 per cent,” Director General, Pharmaceuticals Export Promotion Council of India, Ravi Uday Bhaskar said on the quick estimate numbers released last week by the Centre.

India is now the world's third-largest drugmaker by volume amid the growing demand for the country’s pharmaceutical products in export markets. The US is a key market, which accounts for about 30 per cent of India's annual pharma exports after a nearly 16 per cent increase in fiscal 2024, according to Pharmexcil.

The country's drug shortages as well as the increased use of drugs for lifestyle diseases such as diabetes, hypertension and depression is expected to fuel the demand for India's affordably priced drugs, according to Bhaskar.

According to a report by India Ratings and Research, Indian drugmakers will sustain their revenue improvement in 2024-2025 due to drug shortages in the United States. India is a hub of bulk generic drug manufacturing and drugmakers including Dr Reddy's, Cipla, Sun Pharma derive a significant share of revenue from both the US and Europe.

The world's largest drug market is facing decade-high drug shortages, India Ratings said in a note citing data from with Utah Drug Information Service. There is an active shortage of 233 drugs across 22 therapeutic categories as of April, led mainly by discontinuing production of some drugs, rising demand and delays in shipments, it said, also citing data from the US Food and Drug Administration.

Next Story

Regulatory and procurement challenges, such as delayed tenders and payment issues, contributed to shortages in regions like Karnataka, India .

Title:

Content: BONELA calls for axing of incompetent medical supply officers

  • Says shortage of medicines is a matter of life and death
  • MoH blames it on COVID-19

GAZETTE REPORTER

The Botswana Network on Ethics, Law and HIV/AIDS (BONELA) has called on President Mokgweetsi Masisi to fire incompetent officers for their failure to procure medicines and drugs for public health facilities.

The Assistant Minister of Health and Wellness (MoH), Sethomo Lelatisitswe, recently told Parliament that public health facilities were running short of medicines and condoms, saying the situation was being addressed.

According to BONELA, the situation got worse after the outbreak of COVID-19.

In an interview with The Botswana Gazette this week, the Executive Director of BONELA, Cindy Kelemi, said those responsible for the dearth of drugs and medicines should be fired.

“There is a serious shortage of medicines,” Kelemi said. “Whether you are talking about hypertension medication or anti-retroviral drugs, there are shortages. This is a concern for us because BONELA exists to ensure that the right to health is made a reality in Botswana.”

“The question we often ask is what the ministry is doing to address this, especially for people in hard-to-reach areas? We have always maintained that we have not explored fully our procurement potential, including looking at the private sector.”

She added that in addition to medicines and drugs, condoms are also in short supply at public health facilities. “We have had condom shortages since last year and we were informed that logistical problems were preventing distribution of a donation through the US embassy,” she said. “Central Medical Stores must understand that this is a life and death situation.”

Kelemi expressed hope that the budgetary vote for MoH being the largest, medical supplies to public health facilities will be replenished.

“But we had this problem even before COVID-19,” she noted. “This goes to show that we can throw money at a problem when there are underlying problems.”

The Chief Public Relations Officer at MoH, Dr Christopher Nyanga , has acknowledged the shortage of medicines and drugs at public health facilities but blames it on COVID-19 slowing down production and delivery timelines.

“Health facilities in Botswana and across the world have been experiencing shortages and delayed delivery of certain drugs and medical supplies,” Nyanga said.

He added that the problem has become more pronounced since the last quarter of the 2020/2021 financial year.

Industry consolidations and prioritization of newer, more profitable drugs over older generics also played a role, particularly in chemotherapy drug shortages .

Title:

Content: French health groups put forward proposals to limit the damage of worsening drug shortages

Medicines such as cough syrup, lozenges and ointment are seen on a table in an apartment in Berlin, Tuesday, December 20, 2022. Copyright Stephanie Pilick/dpa via AP
Copyright Stephanie Pilick/dpa via AP
By Lauren Chadwick
Share this articleComments
Share this article

Pharmaceutical companies’ lack of transparency leads to rising drug prices and less control over public resources, the group of health organisations say.

ADVERTISEMENT

A group of French organisations have called for more transparency from pharmaceutical companies as drug shortages increase.

In a joint report, 14 civil society organisations outlined their recommendations to solve a “situation that has only worsened” since 2018.

The French medicines regulator signalled 4,925 drug shortages in 2023, compared to 3,761 in 2022 and 2,160 in 2021.

A 2024 survey from France Assos Santé, which represents patients, found that 44 per cent of people in France said they had faced a drug shortage this year.

One of the pharmacy unions in France has even planned a strike at the end of the month over drug shortages and what they say is worsening access to care.

Each health organisation contributed an article with recommendations for dealing with the drug shortages.

The League Against Cancer urged complete transparency on drug shortages and potential substitutions for health professionals.

They also called for monitoring of medicine stocks and their location in the country to guarantee equal access.

The organisation found in a survey published in February that 78 per cent of health professionals in oncology had been faced with a drug shortage.

Drug shortages or delays have led to anxiety among cancer patients, lost time, and worsening symptoms, the organisation said.

France Assos Santé, meanwhile, wrote that an urgent response should not be to support “the industrial sector which bears serious responsibilities” for abandoning the production of less profitable drugs, relocating drug production, and keeping insufficient medicine stocks.

They would like any cost increases justified by production costs or the risk of withdrawing a drug from the market due to it being unprofitable. They called for cost evaluations to be made public.

Their concerns also range from the use of public money to bring drug production to Europe to new government plans to prevent shortages.

Some changes at the EU level criticised

Last year, the European Commission announced several measures to reform the pharmaceutical industry and address critical drug shortages.

The European Parliament went on to adopt a position on pharmaceutical reform last month, that included “incentives for innovation” and an effort to limit overuse of antibiotics.

The non-profit organisation Prescrire, which focuses on information about medicine, wrote in a chapter they contributed to the report that while some of the European Commission’s measures were welcome, others were concerning.

One of the many measures they rejected included the Commission’s proposal to reduce the number of days of scientific evaluation of drugs from 210 to 180, which they said was necessary time rather than an “administrative obstacle”.

While the NGO welcomed some measures such as government drug shortage prevention plans, it said the Commission should allow EU states to require pharmaceutical companies to have safety stocks of medicine and sanction those that do not respect them.

ADVERTISEMENT

French consumer organisation UFC-Que Choisir and the European Consumer Organisation (BEUC) said that they had hoped MEPs would shorten the length of time for “data protection” to allow generic medicines to be marketed more quickly.

Instead, MEPs approved shortening the period to 7.5 years, “which is almost the same duration as the current 8 years [yet] within the framework of the text adopted by Parliament, companies can gain additional months of protection under certain conditions to reach a total of 8.5 years,” UFC-Que Choisir said.

Share this articleComments

You might also like

Title:

Content: NORTHAMPTON, Mass. (WWLP) – While this shortage of chemotherapy drugs stretches across the country, 22News looks at how the limited amounts of potentially life-saving drugs are impacting cancer care in our area.

It’s a problem, so acute it was recognized by the Biden Administration just last month. The White House noted there’s a shortage of 15 cancer drugs due to manufacturing and supply chain issues.

22News asked Pharmacy Director Michelle Kososki at Mass General Brigham Cooley Dickinson Hospital, to rate the shortage experienced locally on a scale, 5 being a critical shortage and 1 being no shortage at all, “right now I would probably say it is a four. We only have a very small supply of one particular drug.”

Pharmacy Director Michelle Kososki said drug shortages are not uncommon in the healthcare industry however, when faced with potentially life-saving drugs it can get complicated, “Anytime there is a shortage, there’s a risk of not being able to treat patients. Obviously, that is something we want to avoid and we work to the best of our ability with creative solutions to make sure that doesn’t happen.”

Nurse Manager Lisa Martensson at Mass General Care Center at Cooley Dickinson Hospital told 22News, “There’s always the ethical issues of who gets the drug that’s available. It’s supply and demand as you said and looking at what folks had for their disease which ones needed to be treated faster than others based on the aggressiveness of their disease. Those things played in but it was a really difficult decision to sit down and try and decide who would get the drug. We were never in a position where we had to deny anybody.”

Cancer patient Norman Uzdavinis of Whately said he was very concerned when he first heard of the shortage, “I had wondered where in the chemotherapy I would be at, would it have to be delayed for months or years if possible.”

Uzdavinis has not had his medical care compromised but feels for those who have, “I feel for them. I know what I’m going through and that everything is here so it’s perfect for me, but there’s a lot out there that are not as fortunate. I know that.”

“Healthcare providers here were able to mitigate the shortage by using a couple of different tactics. For example, they could switch up a patient’s medication regimen,” Nurse Manager Lisa Martensson said.

“What we did do was use drugs that were in the same classification but not necessarily that specific drug. There are also drug regimens where we could switch around the order to which we gave the drugs so if there was a drug that wasn’t available we are able to do one of the drugs that was available first and do that second drug second. That was able to work out so people didn’t do without and they were able to get what they needed,” Martensson continued.

According to the FDA, the shortage started when one of the major manufacturers of the chemo drug, Accord Healthcare, a company based in India, had to shut down after problems complying with good manufacturing practices were found during an inspection. Now, there is an increased demand from other companies that make these kinds of drugs.

22News contacted some other of the manufacturers of these drugs. Pfizer said they are increasing production by about 40 percent to meet this increased demand.

Local News

Alanna Flood is a reporter who has been a part of the 22News team since 2022. Follow Alanna on X @alannafloodnews and view her bio to see more of her work.

Healthcare systems have responded with a range of coping strategies.

Providers have prioritized and rationed scarce drugs, switched patients to alternative medications within the same class, and adjusted treatment regimens to ensure continuity of care .

Title:

Content: Ireland has been suffering a paracetamol shortage as cases of Covid-19 and the winter flu in the country soared over the festive and new year period.

The revelation was made by Health Minister Stephen Donnelly after his department received notification of a supply issue from the Health Products Regulatory Authority.

It is understood the shortage impacted some prescription paracetamol products.

Read More:Irish people complain of ‘worst ever’ winter bug sweeping country that feels like Covid but isn’t

Two suppliers affected have stated that resupply will be sometime in January 2023.

However, there are other prescription paracetamol suppliers with some stock available on the shelves.

Paracetamol is one of the medicines used most often in Ireland and especially for the flu, aches and pain.

But Mr Donnelly pointed out that there are multiple forms of the drug with different strengths and brands available from various sources.

He said: "In the event that there are some supply issues for individual medicines, alternative options such as alternative strengths and brands, generic medicines will usually be available to ensure continuity of treatment.

"In some cases where the medicine initially prescribed for the patient is unavailable, patients may be switched to a suitable therapeutic alternative following appropriate consultation with a healthcare professional."

The Health Minister said medicine shortages have been increasingly prevalent worldwide over the past decade. The causes of such shortages are multifactorial including shortage of raw materials, manufacturing difficulties and industry consolidations.

He stated: "Medicine shortages can originate at any point in the supply chain. They can involve and impact many stakeholders in different ways as the supply models and clinical use of therapies can vary across national health systems.

"Management of medicines shortages necessitates a multi-faceted, multi stakeholder response to ensure patient safety , continuity of care and protection of public health.

"Patients or their carers who have any concerns in relation to temporary alternative products provided because of medical shortages are advised to speak with their pharmacist or other healthcare [professionals] involved in their care."

Mr Donnelly was responding to a number of written Dail questions on the shortage of medicines.

READ NEXT:

Get breaking news to your inbox by signing up to our newsletter

The FDA allowed importation of chemotherapy drugs from overseas, and the European Commission proposed a "voluntary solidarity mechanism" for EU countries to share medicines and establish early warning